Copper signaling axis as a target for prostate cancer therapeutics.
about
Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinomaPharmacological activity of metal binding agents that alter copper bioavailability.Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.Dynamic internalization and recycling of a metal ion transporter: Cu homeostasis and CTR1, the human Cu⁺ uptake system.The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells.Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells.Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway.Targeting copper in cancer therapy: 'Copper That Cancer'.Developing drugs targeting transition metal homeostasis.Heterogeneous copper concentrations in cancerous human prostate tissues.Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.Copper Signaling in the Brain and Beyond.The comparative effects of diethyldithiocarbamate-copper complex with established proteasome inhibitors on expression levels of CYP1A2/3A4 and their master regulators, aryl hydrocarbon and pregnane X receptor in primary cultures of human hepatocytesDrug Repositioning for Effective Prostate Cancer Treatment.Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications.Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death
P2860
Q26772332-C65C97A6-6B7E-4A6C-8F5F-92E7B7CEDA51Q35587484-E336D01A-EAB5-4A90-AF99-CE5573D6293CQ36557426-04B12609-40F2-4717-A4A1-5CC495F432F2Q36771950-D13A5CC7-35D1-4BD2-BAC3-9DF8DC85A887Q36856920-9EF31B1A-7A5F-41FF-B83A-C0C36590EDCFQ37264685-E3372377-990D-4908-993B-9C509E25617FQ37392908-5068E60E-5981-4E53-8F18-AFFEE037B016Q37580222-1A1B9194-9543-47F8-8D7A-E6D98E81770DQ37719254-2D234D93-06ED-4355-828A-7D00E88349C0Q37739979-CEE8E8A4-32AC-46F2-89F5-AE40733E3710Q38575035-D62A81AC-8BD5-496F-912C-BC9C5400A658Q39063848-D8F96EE0-F514-4356-A47F-3CFD2C16F8EDQ41716252-FCE10DAB-D9B3-40BD-A6EE-EA9B1F078D12Q46185130-B8AE7BF9-A86E-4FCA-A224-69C8BF4A6467Q46766311-330EB088-CB18-4DB3-A400-4413A85ABF02Q51642518-6756965D-D703-41CC-B205-06A6D8E92021Q55254671-E5F5F301-C3D6-4FDC-A254-1234F19B86BDQ55380579-17F4DBC6-7CAC-4A54-8F70-E9C4762352F8Q58744474-4DD66299-197C-46BF-869A-63EBF1E2CB83
P2860
Copper signaling axis as a target for prostate cancer therapeutics.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Copper signaling axis as a target for prostate cancer therapeutics.
@en
type
label
Copper signaling axis as a target for prostate cancer therapeutics.
@en
prefLabel
Copper signaling axis as a target for prostate cancer therapeutics.
@en
P2093
P2860
P1433
P1476
Copper signaling axis as a target for prostate cancer therapeutics.
@en
P2093
Daniel J George
Donald P McDonnell
Michael R Zalutsky
Rachid Safi
Satish K Chitneni
P2860
P304
P356
10.1158/0008-5472.CAN-13-3527
P407
P577
2014-10-01T00:00:00Z